Table 1 Demography of case cohort
Characteristics | Malignant, n(%) | Borderline, n(%) | Benign, n(%) | Total | P value |
|---|---|---|---|---|---|
Number (n) | 95 (73.1) | 17 (13.1) | 18 (13.8) | 130 (100) | |
Age (mean ± SD) | 51 ± 12 | 46 ± 16 | 50 ± 14 | 51 ± 12 | 0. 3378 |
Mensus status | 0.602 | ||||
Pre mensus | 28 (29.5) | 7 (41.2) | 5 (27.8) | 40 (30.8) | |
Post mensus | 67 (70.5) | 10 (58.8) | 13 (72.2) | 90 (69.2) | |
FIGO stage | < 0.001 | ||||
I and II | 36 (37.9) | 17 (100) | --- | 53 (40.8) | |
III and IV | 59 (62.1) | 0 (0) | --- | 59 (45.4) | |
Grade | < 0.001 | ||||
I and II | 39 (41.1) | 17 (100) | --- | 56 (50) | |
III and UD | 56 (58.9) | 0 (0) | --- | 56 (50) | |
Histopathology | < 0.001 | ||||
Serous | 57 (60) | 8 (47.1) | 9 (50) | 74 (56.9) | |
Mucinous | 10 (10.5) | 8 (47.1) | 9 (50) | 27 (20.8) | |
Endometrioid | 5 (5.3) | 1 (5.9) | 0 (0) | 6 (4.6) | |
Clear cell | 5 (5.3) | 0 (0) | 0 (0) | 5 (3.8) | |
Poorly differentiated | 18 (18.9) | 0 (0) | 0 (0) | 18 (13.9) | |
Bilateral affliction | 59 (45.4) | 5 (29.4) | 0 (0) | 64 (49.2) | ND* |
Pre-Op CA125 | < 0.001 | ||||
0–35 U/mL | 5 (5.3) | 5 (29.4) | 12 (66.7) | 22 (16.9) | |
35–110 in U/mL | 7 (7.4) | 6 (35.3) | 5 (27.8) | 18 (13.8) | |
110–1000 U/mL | 51 (53.7) | 5 (29.4) | 1 (5.5) | 57 (43.9) | |
> 1000 U/mL | 32 (33.7) | 1 (5.9) | 0 (0) | 33 (25.4) | |
Ascites | < 0.001 | ||||
Nil | 17 (17.9) | 6 (35.3) | 14 (77.8) | 37 (28.5) | |
< 500 ml | 25 (26.3) | 10 (58.8) | 4 (22.2) | 39 (30) | |
> 500 ml | 53 (55.8) | 1 (5.9) | 0 (0) | 54 (41.5) | |
Residual disease | < 0.001 | ||||
Nil | 44 (46.3) | 12 (70.6) | 18 (100) | 74 (56.9) | |
< 1 | 27 (28.4) | 2 (11.8) | 0 (0) | 29 (22.3) | |
> 1 | 22 (23.2) | 0 (0) | 0 (0) | 22 (16.9) | |
Not known | 2 (2.1) | 3 (17.6) | 0 (0) | 5 (3.9) |